Drug name
Last update: Jul 2026Ivermectin
Developer(s)
Drug information
Not provided
Ivermectin
Not provided
Small molecule
Not provided
Ivermectin is a broad-spectrum anthelmintic that possesses significant potential as a first-in-class endectocide providing vector-based malaria control. Ivermectin functions by binding glutamate-gated chloride channels present in parasital nerve and muscle cells, which results in the elimination of the organism. An extended-release oral ivermectin formulation known as LYN-163 is currently being developed by Lyndra Therapeutics and is undergoing phase I clinical trials. This ultra-long acting, oral drug delivery system is based on their proprietary LYNX™ technology which supports once fortnightly dosing. Other long-acting ivermectin formulations are in the pre-clinical phase and include a polymer-based injectable developed by MedinCell utilising their proprietary BEPO® drug delivery system.
Unknown
Unknown
Therapeutic area(s)
- Malaria
- COVID 19
- Other(s) : "other parasitic infections"
- Pre-Exposure Prophylaxis (PrEP)
- Post-Exposure Prophylaxis (PEP)
- Treatment
Administration route
Oral, Subcutaneous
Associated long-acting platforms
Oral solid form, Polymer-based particles
Use of drug
- Administered by a nurse
- Administered by a specialty health worker
- Self-administered
- To be determined
Not provided
Dosage
Not provided
Not provided
Not provided
Not provided
Not provided
Additional information
Developer(s)
Merck / MSD
Dr. William C. Campbell conducted his co-recipient 2015 Physiology or Medicine Nobel Prize-winning Work at Merck Research Laboratories. He received the prize with Satoshi Omura for the discovery of avermectin which led to Merck’s development of ivermectin, to treat river blindness. They share the prize with Youyou Tu for her discoveries concerning a novel therapy against malaria.
Various generic manufacturersVarious generic manufacturers
Ivermectin 3mg manufactured buy generic manufactures including: ARROW LAB, BIOGARAN, CRISTERS, EG, EG LABO, PIERRE FABRE, SANDOZ, SIGILLATA, SUBSTIPHARM, TEVA, VIATRIS, ZENTIVA, Taj Pharmaceuticals, Dr. Reddy's labs.
Drug structure
Scale-up and manufacturing prospects
Compound is commercially manufactured.
(1) Fermentation & Extraction tanks:Â Bacterial fermentation vessels to produce avermectin and its subsequent extraction from the fermentation broth. (2) Hydrogenation reactors: Allows the conversion of avermectin to ivermectin by selective hydrogenation. (3) Filtration systems:Â Removes impurities from the ivermectin solution. (4) Crystallizers:Â Vessels used to crystallize ivermectin from the solution. (5) Dryers:Â Required to remove solvent from the crystallized ivermectin. (6) Packaging equipment:Â Machinery to package the final drug product.
Avermectin derivatives such as ivermectin are unstable in acidic and alkaline conditions, in addition to being sensitive to strong light. Product formulations containing avermectins usually include antioxidant excipients as they susceptible to chemical oxidation processes.
(1) Identification of residual impurities: High-performance liquid chromatography (HPLC), gas chromatography (GC), mass spectrometry (MS). (2) Determine concentration: Ultraviolet-visible spectrophotometry. (3) Elucidate melting point and identify polymorphic forms: Differential scanning calorimetry. (4) Analyse crystal structure and determine polymorphic forms: X-ray powder diffraction (XRPD). (5) Drug solubility: Dissolution testing apparatus.
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Lyndra’s proprietary LYNX™ drug delivery platform is a novel approach to oral drug delivery that enables once-a-week or even once-a-month dosing. Key proprietary features include: (1) A flexible core that allows the dosage form to maintain its desired shape in the stomach, preventing premature passage into the small intestine. (2) Linkers connecting dosage form arms to the core. These linkers are designed to soften and disintegrate, allowing the dosage form to safely exit the body. (3) A proprietary coating that makes the capsule easy to swallow and ensures it remains intact in the oesophagus.
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
Long-acting injectable ivermectin formulation
This invention relates to novel, long-acting injectable formulations. These formulations comprise: (a) a therapeutic agent selected from the group consisting of, e.g., insecticides, acaricides, parasiticides, growth enhancers and oil-soluble NASIDS; (b) hydrogenated castor oil and (c) a hydrophobic carrier comprising: (i) triacetin, benzyl benzoate or ethyl oleate or a combination thereof; and (ii) acylated monoglycerides, propyl dicaprylates/dicaprates or caprylic/capric acid triglycerides or a combination thereof. Also provided herein is a method for the treatment or prevention of various disease states by the parental administration of the invention formulations.
WO1999027906
Formulation
Merck Sharp & Dohme Corp; Merial LLS (acquired by BI)
Long-acting injectable parasiticide formulation of specific excipients and therapeutic agent such as ivermectin, for various use including the prevention and treatment of parasitic infestation
September 14, 2018
Expired
Ivermectin compound
Derivatives of C-076 are described in which the C-076 molecule, as series of macrolides, has a specific unsaturation, at the 22,23-position, catalytically reduced. Further reaction of the reduced C-076 compounds are also possible. The compounds thus produced have profound anthelmintic, insecticidal, ectoparasiticidal and acaracidal activity. Compositions containing the described C-076 derivatives as the active ingredient thereof are also disclosed.
US4199569
Compound
Merck & Co, Inc.
Not provided
April 22, 1997
Expired